Fig 1.
Schematic diagram for the study design.
Note: INR: International Normalized Ratio, TTR: Time to Therapeutic Range.
Fig 2.
Flow chart of study cohort selection.
Note: INR: International Normalized Ratio, TTR: Time to Therapeutic Range; NAFLD: Nonalcoholic Fatty Liver Disease; NASH: Nonalcoholic Steatohepatitis; HBV: Hepatitis B Virus Infection, HCV: Hepatitis C Virus Infection.
Table 1.
Demographic and clinical characteristics of study population selected from health plan data between 2010 – 2015.
Table 2.
Demographic and clinical characteristics using propensity score fine stratification, USA 2010 – 2015.
Fig 3.
Adjusted effect estimate of NAFLD/NASH on average daily dose of warfarin using the propensity score stratification approach after the first 2 months of warfarin use.
Note: NAFLD: Nonalcoholic Fatty Liver Disease; NASH: Nonalcoholic Steatohepatitis; ADD: Average Daily Dose.
Fig 4.
Adjusted odds ratio of TTR>60% among NAFLD/NASH vs Non-NAFLD/NASH using the propensity score stratification approach after warfarin initiation.
Note: NAFLD: Nonalcoholic Fatty Liver Disease; NASH: Nonalcoholic Steatohepatitis; TTR: Time to Therapeutic Range.